[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HRP20201494T1 - Heteroaryl carboxamide compounds as inhibitors of ripk2 - Google Patents

Heteroaryl carboxamide compounds as inhibitors of ripk2 Download PDF

Info

Publication number
HRP20201494T1
HRP20201494T1 HRP20201494TT HRP20201494T HRP20201494T1 HR P20201494 T1 HRP20201494 T1 HR P20201494T1 HR P20201494T T HRP20201494T T HR P20201494TT HR P20201494 T HRP20201494 T HR P20201494T HR P20201494 T1 HRP20201494 T1 HR P20201494T1
Authority
HR
Croatia
Prior art keywords
6alkyl
optionally substituted
alkyl
image
cycloalkyl
Prior art date
Application number
HRP20201494TT
Other languages
Croatian (hr)
Inventor
Pingrong Liu
Craig Andrew Miller
Maolin Yu
Zhonghua Zhang
Sabine Ruppel
Anil K. Padyana
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of HRP20201494T1 publication Critical patent/HRP20201494T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)

Claims (27)

1. Spoj, naznačen time, da je predstavljen formulom (I): [image] ili njegova farmaceutski prihvatljiva sol, gdje: X je N i Y je CH; ili X je CH i Y je N; HET je 5-člani heteroarilni prsten koji sadrži jedan do tri heteroatoma odabrana od dušika i sumpora, pri čemu je svaki heteroarilni prsten opcijski supstituiran s jednom do dvije supstituentske skupine neovisno odabrane od R3 i R4; ili HET je 5-člani heteroarilni prsten koji sadrži jedan do tri heteroatoma odabrana od dušika i sumpora, pri čemu je svaki heteroarilni prsten supstituiran s dvije supstituentske skupine odabrane od Ra i Rb , gdje Ra i Rbzajedno s atomima na koje su priključeni, tvore 5-6-člani heterociklički ili heteroarilni prsten koji može biti opcijski supstituiran s jednim do dva supstituenta odabrana od R3 i R4; R1 je vodik ili F; R2 je C1-3 alkil ili Cl; svaki od R3i R4 je neovisno odabran od sljedećih: (a) –H, (b) –O R5, (c) -O-C1-6alkil-O-C1-3 alkil, (d) –O-C3-6 cikloalkil, (e) -C(O)R5, (f) C1-6alkil opcijski supstituiran s jednim do tri –OH, fluorom, heterociklilom opcijski supstituiranim s okso, C3-6 cikloalkilom, –CO2R5, -O-C1-6alkilom, arilom, -N(R5)(R6) ili C(O)N(R5)(R6), (g) C3-6 cikloalkil opcijski supstituiran s jednim do tri –OH, jednim do tri fluora, C1-6alkilom, -OC1-6alkilom, C1-6alkil-OC1-6alkilom, C1-6alkilom-OH, CF3, OC3-6cikloalkilom, -CO2H, -CO2R5, C3-6cikloalkilom, 5-6-članim heteroarilom, C3-6 heterociklilom, N(R5)(R6) ili C(O)N(R5)(R6), (h) –CO2R5, (i) -C(O)N(R5)(R6), (j) –S(O)2N(R5)(R6), (k) –S(O)n-R5, (l) 5-6-člana heteroarilna skupina opcijski supstituirana s jednom do tri skupine odabrane od sljedećih: C1-6alkil, C3-6cikloalkil, halogen, -CF3, -OH, -(CH2)nCO2R5, C(O)N(R5)(R6), -N(R5)(R6), -NH-SO2C1-6alkil, C1-6alkoksil, C1-6alkil-O-C1-3 alkil, C1-6alkilhidroksil, C1-3alkil-CN, okso, fenil opcijski supstituiran s halogenom i -S(O)nC1-6alkil, (m) 4-10-člana monociklička, biciklička ili spirociklička heterociklilna skupina koja sadrži N, S ili O, pri čemu je svaki heterocikl opcijski supstituiran s 1-3 supstituenta odabrana od 3-6-članog heterocikličkog prstena, halogena, -C1-3alkila, -C1-3alkil–O-C1-3alkila i -C1-3alkila-C(O)N(R5)(R6), (n) aril, (o) -N(R5)(R6); svaki od R5 i R6 je neovisno odabran od sljedećih: –H, 4-6-člani heterociklil, -C(O)-C1-3 alkil, C(O)-C1-3 cikloalkil i –(C1-C6)alkil, gdje je svaki od R5 i R6 neovisno opcijski supstituiran sa sljedećima: –OH, C3-6 cikloalkil, -C1-3alkil, –O-C1-3alkil, -NH-C1-3 alkil ili –N-(C1-3-alkil)2; ili R5 i R6 zajedno s dušikovim atomom na kojega su priključeni, tvore 4-6-člani heterociklički prsten opcijski supstituiran s metilom; i n je 0, 1 ili 2.1. A compound, indicated by the fact that it is represented by formula (I): [image] or a pharmaceutically acceptable salt thereof, where: X is N and Y is CH; or X is CH and Y is N; HET is a 5-membered heteroaryl ring containing one to three heteroatoms selected from nitrogen and sulfur, each heteroaryl ring being optionally substituted with one to two substituent groups independently selected from R3 and R4; or HET is a 5-membered heteroaryl ring containing one to three heteroatoms selected from nitrogen and sulfur, where each heteroaryl ring is substituted with two substituent groups selected from Ra and Rb, where Ra and Rb, together with the atoms to which they are attached, form 5- a 6-membered heterocyclic or heteroaryl ring which may be optionally substituted with one to two substituents selected from R3 and R4; R 1 is hydrogen or F; R 2 is C 1-3 alkyl or Cl; each of R3 and R4 is independently selected from the following: (a) –H, (b) –O R5, (c) -O-C1-6alkyl-O-C1-3 alkyl, (d) –O-C3-6 cycloalkyl, (e) -C(O)R5, (f) C1-6alkyl optionally substituted with one to three –OH, fluorine, heterocyclyl optionally substituted with oxo, C3-6cycloalkyl, –CO2R5, -O-C1-6alkyl, aryl, -N(R5)(R6) or C (O)N(R5)(R6), (g) C3-6 cycloalkyl optionally substituted with one to three –OH, one to three fluorines, C1-6alkyl, -OC1-6alkyl, C1-6alkyl-OC1-6alkyl, C1-6alkyl-OH, CF3, OC3-6cycloalkyl, -CO2H, -CO2R5, C3-6cycloalkyl, 5-6-membered heteroaryl, C3-6 heterocyclyl, N(R5)(R6) or C(O)N(R5)(R6), (h) –CO2R5, (i) -C(O)N(R5)(R6), (j) –S(O)2N(R5)(R6), (k) –S(O)n-R5, (l) 5-6 membered heteroaryl group optionally substituted with one to three groups selected from the following: C1-6alkyl, C3-6cycloalkyl, halogen, -CF3, -OH, -(CH2)nCO2R5, C(O)N(R5 )(R6), -N(R5)(R6), -NH-SO2C1-6alkyl, C1-6alkyl, C1-6alkyl-O-C1-3 alkyl, C1-6alkylhydroxyl, C1-3alkyl-CN, oxo, phenyl optional substituted with halogen and -S(O)nC1-6alkyl, (m) a 4-10-membered monocyclic, bicyclic or spirocyclic heterocyclic group containing N, S or O, each heterocycle being optionally substituted with 1-3 substituents selected from a 3-6-membered heterocyclic ring, halogen, -C1- 3alkyl, -C1-3alkyl-O-C1-3alkyl and -C1-3alkyl-C(O)N(R5)(R6), (n) aryl, (o) -N(R 5 )(R 6 ); each of R5 and R6 is independently selected from the following: -H, 4-6 membered heterocyclyl, -C(O)-C1-3 alkyl, C(O)-C1-3 cycloalkyl and -(C1-C6)alkyl, wherein each of R5 and R6 is independently optionally substituted with the following: -OH, C3-6 cycloalkyl, -C1-3alkyl, -O-C1-3alkyl, -NH-C1-3 alkyl or -N-(C1-3-alkyl) )2; or R5 and R6, together with the nitrogen atom to which they are attached, form a 4-6-membered heterocyclic ring optionally substituted with methyl; and n is 0, 1 or 2. 2. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time, da: X je N i Y je CH; ili X je CH i Y je N; Het je 5-člani heteroarilni prsten odabran od pirazolila, imidazolila, tiazolila i tiadiazolila, pri čemu je svaki heteroarilni prsten opcijski supstituiran s jednom do dvije supstituentske skupine neovisno odabrane od R3 i R4; ili Het je 5-člani heteroarilni prsten odabran od pirazolila i imidazolila, pri čemu je svaki heteroarilni prsten supstituiran s dvije supstituentske skupine odabrane od Ra i Rb , gdje Ra i Rbzajedno s atomima na koje su priključeni, tvore 5-6-člani heterociklički ili heteroarilni prsten koji može biti opcijski supstituiran s jednim do dva supstituenta odabrana od R3 i R4; R1 je vodik ili F; R2 je C1-3 alkil ili Cl; svaki od R3i R4 je neovisno odabran od sljedećih: (a) –H, (b) –O R5, (c) -O-C1-6alkil-O-C1-3 alkil, (d) –O-C3-6 cikloalkil, (e) -C(O)R5, (f) C1-6alkil opcijski supstituiran s jednim do tri –OH, fluorom, heterociklilom opcijski supstituiranim s okso, C3-6 cikloalkilom, –CO2R5, -O-C1-6alkilom, arilom, -N(R5)(R6) ili C(O)N(R5)(R6), (g) C3-6 cikloalkil opcijski supstituiran s jednim do tri –OH, jednim do tri fluora, C1-6alkilom, -OC1-6alkilom, C1-6alkil-OC1-6alkilom, C1-6alkilom-OH, CF3, OC3-6cikloalkilom, -CO2H, -CO2R5, C3-6cikloalkilom, 5-6-članim heteroarilom, C3-6 heterociklilom, N(R5)(R6) ili C(O)N(R5)(R6), (h) –CO2R5, (i) -C(O)N(R5)(R6), (j) –S(O)2N(R5)(R6), (k) –S(O)n-R5, (l) 5-6-člana heteroarilna skupina opcijski supstituirana s jednom do tri skupine odabrane od sljedećih: C1-6alkil, C3-6cikloalkil, halogen, -CF3, -OH, -(CH2)nCO2R5, C(O)N(R5)(R6), -N(R5)(R6), -NH-SO2C1-6alkil, C1-6alkoksil, C1-6alkil-O-C1-3 alkil, C1-6alkilhidroksil, C1-3alkil-CN, okso, fenil opcijski supstituiran s halogenom i -S(O)nC1-6alkil, (m) 4-10-člana monociklička, biciklička ili spirociklička heterociklilna skupina koja sadrži N, S ili O, pri čemu je svaki heterocikl opcijski supstituiran s 1-3 supstituenta odabrana od 3-6-članog heterocikličkog prstena, halogena, C1-3alkila i C1-3alkila-C(O)N(R5)(R6), (n) aril, (o) -N(R5)(R6); svaki od R5 i R6 je neovisno odabran od sljedećih: –H, 4-6-člani heterociklil, -C(O)-C1-3 alkil-C(O)-C1-3 cikloalkil i –(C1-C6)alkil opcijski supstituiran s –OH, C3-6 cikloalkil, -NH-C1-3 alkil ili –N-(C1-3-alkil)2; ili R5 i R6 zajedno s dušikovim atomom na kojega su priključeni, tvore 5-6-člani heterociklički prsten opcijski supstituiran s metilom; i n je 0 ili 2.2. The compound according to patent claim 1 or its pharmaceutically acceptable salt, characterized in that: X is N and Y is CH; or X is CH and Y is N; Het is a 5-membered heteroaryl ring selected from pyrazolyl, imidazolyl, thiazolyl and thiadiazolyl, each heteroaryl ring being optionally substituted with one to two substituent groups independently selected from R3 and R4; or Het is a 5-membered heteroaryl ring selected from pyrazolyl and imidazolyl, whereby each heteroaryl ring is substituted with two substituent groups selected from Ra and Rb, where Ra and Rb, together with the atoms to which they are attached, form 5-6-membered heterocyclic or heteroaryl a ring which may be optionally substituted with one to two substituents selected from R3 and R4; R 1 is hydrogen or F; R 2 is C 1-3 alkyl or Cl; each of R3 and R4 is independently selected from the following: (a) –H, (b) –O R5, (c) -O-C1-6alkyl-O-C1-3 alkyl, (d) –O-C3-6 cycloalkyl, (e) -C(O)R5, (f) C1-6alkyl optionally substituted with one to three –OH, fluorine, heterocyclyl optionally substituted with oxo, C3-6cycloalkyl, –CO2R5, -O-C1-6alkyl, aryl, -N(R5)(R6) or C (O)N(R5)(R6), (g) C3-6 cycloalkyl optionally substituted with one to three –OH, one to three fluorines, C1-6alkyl, -OC1-6alkyl, C1-6alkyl-OC1-6alkyl, C1-6alkyl-OH, CF3, OC3-6cycloalkyl, -CO2H, -CO2R5, C3-6cycloalkyl, 5-6-membered heteroaryl, C3-6 heterocyclyl, N(R5)(R6) or C(O)N(R5)(R6), (h) –CO2R5, (i) -C(O)N(R5)(R6), (j) –S(O)2N(R5)(R6), (k) –S(O)n-R5, (l) 5-6 membered heteroaryl group optionally substituted with one to three groups selected from the following: C1-6alkyl, C3-6cycloalkyl, halogen, -CF3, -OH, -(CH2)nCO2R5, C(O)N(R5 )(R6), -N(R5)(R6), -NH-SO2C1-6alkyl, C1-6alkyl, C1-6alkyl-O-C1-3 alkyl, C1-6alkylhydroxyl, C1-3alkyl-CN, oxo, phenyl optional substituted with halogen and -S(O)nC1-6alkyl, (m) a 4-10 membered monocyclic, bicyclic or spirocyclic heterocyclic group containing N, S or O, each heterocycle being optionally substituted with 1-3 substituents selected from a 3-6 membered heterocyclic ring, halogen, C1-3alkyl and C1-3alkyl-C(O)N(R5)(R6), (n) aryl, (o) -N(R 5 )(R 6 ); each of R5 and R6 is independently selected from the following: -H, 4-6 membered heterocyclyl, -C(O)-C1-3 alkyl-C(O)-C1-3 cycloalkyl and -(C1-C6)alkyl optionally substituted with –OH, C3-6 cycloalkyl, -NH-C1-3 alkyl or –N-(C1-3-alkyl)2; or R5 and R6, together with the nitrogen atom to which they are attached, form a 5-6-membered heterocyclic ring optionally substituted with methyl; and n is 0 or 2. 3. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time, da: HET je 5-člani heteroarilni prsten odabran od pirazolila, imidazolila, tiazolila i tiadiazolila, pri čemu je svaki heteroarilni prsten opcijski supstituiran s jednom do dvije supstituentske skupine neovisno odabrane od R3 i R4; svaki od R3i R4 je neovisno odabran od sljedećih: (a) –H, (b) –O R5, (c) -O-C1-6alkil-O-C1-3 alkil, (d) –O-C3-6 cikloalkil, (e) -C(O)R5, (f) C1-6alkil opcijski supstituiran s jednim do tri –OH, fluorom, heterociklilom opcijski supstituiranim s okso, C3-6 cikloalkilom, –CO2R5, -O-C1-6alkilom, arilom, -N(R5)(R6) ili C(O)N(R5)(R6), (g) C3-6 cikloalkil opcijski supstituiran s jednim do tri –OH, jednim do tri fluora, C1-6alkilom, -OC1-6alkilom, C1-6alkil-OC1-6alkilom, C1-6alkilom-OH, CF3, OC3-6cikloalkilom, -CO2H, -CO2R5, C3-6cikloalkilom, 5-6-članim heteroarilom, C3-6 heterociklilom, N(R5)(R6) ili C(O)N(R5)(R6), (h) –CO2R5, (i) -C(O)N(R5)(R6), (j) –S(O)2N(R5)(R6), (k) –S(O)n-R5, (l) 5-6-člana heteroarilna skupina opcijski supstituirana s jednom do tri skupine odabrane od sljedećih: C1-6alkil, C3-6cikloalkil, halogen, -CF3, -OH, -(CH2)nCO2R5, C(O)N(R5)(R6), -N(R5)(R6), -NH-SO2C1-6alkil, C1-6alkoksil, C1-6alkil-O-C1-3 alkil, C1-6alkilhidroksil, C1-3alkil-CN, okso, fenil opcijski supstituiran s halogenom i -S(O)nC1-6alkil, (m) 4-10-člana monociklička, biciklička ili spirociklička heterociklilna skupina koja sadrži N, S ili O, pri čemu je svaki heterocikl opcijski supstituiran s 1-3 supstituenta odabrana od 3-6-članog heterocikličkog prstena, halogena, C1-3alkila i C1-3alkila-C(O)N(R5)(R6), (n) aril, (o) -N(R5)(R6); svaki od R5 i R6 je neovisno odabran od sljedećih: –H, 4-6-člani heterociklil, -C(O)-C1-3 alkil-C(O)-C1-3 cikloalkil i –(C1-C6)alkil opcijski supstituiran s –OH, C3-6 cikloalkil, -NH-C1-3 alkil ili –N-(C1-3-alkil)2; ili R5 i R6 zajedno s dušikovim atomom na kojega su priključeni, tvore 5-6-člani heterociklički prsten opcijski supstituiran s metilom; i n je 0 ili 2.3. The compound according to patent claim 1 or its pharmaceutically acceptable salt, characterized in that: HET is a 5-membered heteroaryl ring selected from pyrazolyl, imidazolyl, thiazolyl and thiadiazolyl, each heteroaryl ring being optionally substituted with one to two substituent groups independently selected from R3 and R4; each of R3 and R4 is independently selected from the following: (a) –H, (b) –O R5, (c) -O-C1-6alkyl-O-C1-3 alkyl, (d) –O-C3-6 cycloalkyl, (e) -C(O)R5, (f) C1-6alkyl optionally substituted with one to three –OH, fluorine, heterocyclyl optionally substituted with oxo, C3-6cycloalkyl, –CO2R5, -O-C1-6alkyl, aryl, -N(R5)(R6) or C (O)N(R5)(R6), (g) C3-6 cycloalkyl optionally substituted with one to three –OH, one to three fluorines, C1-6alkyl, -OC1-6alkyl, C1-6alkyl-OC1-6alkyl, C1-6alkyl-OH, CF3, OC3-6cycloalkyl, -CO2H, -CO2R5, C3-6cycloalkyl, 5-6-membered heteroaryl, C3-6 heterocyclyl, N(R5)(R6) or C(O)N(R5)(R6), (h) –CO2R5, (i) -C(O)N(R5)(R6), (j) –S(O)2N(R5)(R6), (k) –S(O)n-R5, (l) 5-6 membered heteroaryl group optionally substituted with one to three groups selected from the following: C1-6alkyl, C3-6cycloalkyl, halogen, -CF3, -OH, -(CH2)nCO2R5, C(O)N(R5 )(R6), -N(R5)(R6), -NH-SO2C1-6alkyl, C1-6alkyl, C1-6alkyl-O-C1-3 alkyl, C1-6alkylhydroxyl, C1-3alkyl-CN, oxo, phenyl optional substituted with halogen and -S(O)nC1-6alkyl, (m) a 4-10 membered monocyclic, bicyclic or spirocyclic heterocyclic group containing N, S or O, each heterocycle being optionally substituted with 1-3 substituents selected from a 3-6 membered heterocyclic ring, halogen, C1-3alkyl and C1-3alkyl-C(O)N(R5)(R6), (n) aryl, (o) -N(R 5 )(R 6 ); each of R5 and R6 is independently selected from the following: -H, 4-6 membered heterocyclyl, -C(O)-C1-3 alkyl-C(O)-C1-3 cycloalkyl and -(C1-C6)alkyl optionally substituted with –OH, C3-6 cycloalkyl, -NH-C1-3 alkyl or –N-(C1-3-alkyl)2; or R5 and R6, together with the nitrogen atom to which they are attached, form a 5-6-membered heterocyclic ring optionally substituted with methyl; and n is 0 or 2. 4. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time, da: HET je 5-člani heteroarilni prsten odabran od pirazolila i imidazolila, pri čemu je svaki heteroarilni prsten supstituiran s dvije supstituentske skupine odabrane od Ra i Rb; pri čemu Ra i Rbzajedno s atomima na koje su priključeni, tvore 5-6-člani heterociklički ili heteroarilni prsten koji može biti opcijski supstituiran s jednim do dva supstituenta odabrana od R3 i R4; svaki od R3i R4 je neovisno odabran od sljedećih: (a) –H, (b) –O R5, (c) -O-C1-6alkil-O- C1-3 alkil, (d) –O-C3-6 cikloalkil, (e) -C(O)R5, (f) C1-6alkil opcijski supstituiran s jednim do tri –OH, fluorom, heterociklilom opcijski supstituiranim s okso, C3-6 cikloalkilom, –CO2R5, -O-C1-6alkilom, arilom, -N(R5)(R6) ili C(O)N(R5)(R6), (g) C3-6 cikloalkil opcijski supstituiran s jednim do tri –OH, jednim do tri fluora, C1-6alkilom, -OC1-6alkilom, C1-6alkil-OC1-6alkilom, C1-6alkilom-OH, CF3, OC3-6cikloalkilom, -CO2H, -CO2R5, C3-6cikloalkilom, 5-6-članim heteroarilom, C3-6 heterociklilom, N(R5)(R6) ili C(O)N(R5)(R6), (h) –CO2R5, (i) -C(O)N(R5)(R6), (j) –S(O)2N(R5)(R6), (k) –S(O)n-R5, (l) 5-6-člana heteroarilna skupina opcijski supstituirana s jednom do tri skupine odabrane od sljedećih: C1-6alkil, C3-6cikloalkil, halogen, -CF3, -OH, -(CH2)nCO2R5, C(O)N(R5)(R6), -N(R5)(R6), -NH-SO2C1-6alkil, C1-6alkoksil, C1-6alkil-O-C1-3 alkil, C1-6alkilhidroksil, C1-3alkil-CN, okso, fenil opcijski supstituiran s halogenom i -S(O)nC1-6alkil, (m) 4-10-člana monociklička, biciklička ili spirociklička heterociklilna skupina koja sadrži N, S ili O, pri čemu je svaki heterocikl opcijski supstituiran s 1-3 supstituenta odabrana od 3-6-članog heterocikličkog prstena, halogena, C1-3alkila i C1-3alkila-C(O)N(R5)(R6), (n) aril, (o) -N(R5)(R6); svaki od R5 i R6 je neovisno odabran od sljedećih: –H, 4-6-člani heterociklil, -C(O)-C1-3 alkil-C(O)-C1-3 cikloalkil i –(C1-C6)alkil opcijski supstituiran s –OH, C3-6 cikloalkil, -NH-C1-3 alkil ili –N-(C1-3-alkil)2; ili R5 i R6 zajedno s dušikovim atomom na kojega su priključeni, tvore 6-člani heterociklički prsten opcijski supstituiran s metilom; i n je 0 ili 2.4. The compound according to patent claim 1 or its pharmaceutically acceptable salt, characterized in that: HET is a 5-membered heteroaryl ring selected from pyrazolyl and imidazolyl, wherein each heteroaryl ring is substituted with two substituent groups selected from Ra and Rb; whereby Ra and Rb, together with the atoms to which they are attached, form a 5-6-membered heterocyclic or heteroaryl ring that can be optionally substituted with one to two substituents selected from R3 and R4; each of R3 and R4 is independently selected from the following: (a) –H, (b) –O R5, (c) -O-C1-6alkyl-O-C1-3 alkyl, (d) –O-C3-6 cycloalkyl, (e) -C(O)R5, (f) C1-6alkyl optionally substituted with one to three –OH, fluorine, heterocyclyl optionally substituted with oxo, C3-6cycloalkyl, –CO2R5, -O-C1-6alkyl, aryl, -N(R5)(R6) or C (O)N(R5)(R6), (g) C3-6 cycloalkyl optionally substituted with one to three –OH, one to three fluorines, C1-6alkyl, -OC1-6alkyl, C1-6alkyl-OC1-6alkyl, C1-6alkyl-OH, CF3, OC3-6cycloalkyl, -CO2H, -CO2R5, C3-6cycloalkyl, 5-6-membered heteroaryl, C3-6 heterocyclyl, N(R5)(R6) or C(O)N(R5)(R6), (h) –CO2R5, (i) -C(O)N(R5)(R6), (j) –S(O)2N(R5)(R6), (k) –S(O)n-R5, (l) 5-6 membered heteroaryl group optionally substituted with one to three groups selected from the following: C1-6alkyl, C3-6cycloalkyl, halogen, -CF3, -OH, -(CH2)nCO2R5, C(O)N(R5 )(R6), -N(R5)(R6), -NH-SO2C1-6alkyl, C1-6alkyl, C1-6alkyl-O-C1-3 alkyl, C1-6alkylhydroxyl, C1-3alkyl-CN, oxo, phenyl optional substituted with halogen and -S(O)nC1-6alkyl, (m) a 4-10 membered monocyclic, bicyclic or spirocyclic heterocyclic group containing N, S or O, each heterocycle being optionally substituted with 1-3 substituents selected from a 3-6 membered heterocyclic ring, halogen, C1-3alkyl and C1-3alkyl-C(O)N(R5)(R6), (n) aryl, (o) -N(R 5 )(R 6 ); each of R5 and R6 is independently selected from the following: -H, 4-6 membered heterocyclyl, -C(O)-C1-3 alkyl-C(O)-C1-3 cycloalkyl and -(C1-C6)alkyl optionally substituted with –OH, C3-6 cycloalkyl, -NH-C1-3 alkyl or –N-(C1-3-alkyl)2; or R5 and R6, together with the nitrogen atom to which they are attached, form a 6-membered heterocyclic ring optionally substituted with methyl; and n is 0 or 2. 5. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time, da: HET je pirazolil opcijski supstituiran s jednom do dvije supstituentske skupine odabrane od R3 i R4.5. A compound according to claim 1 or a pharmaceutically acceptable salt thereof, characterized in that: HET is pyrazolyl optionally substituted with one to two substituent groups selected from R3 and R4. 6. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time, da: HET je 5-člani heteroarilni prsten odabran od pirazolila i imidazolila, pri čemu je svaki heteroarilni prsten supstituiran s dvije supstituentske skupine odabrane od Ra i Rb; pri čemu Ra i Rbzajedno s atomima na koje su priključeni, tvore 5-6-člani heteroarilni prsten tako da je HET biciklički heteroarilni prsten odabran od imidazopiridina i pirazolopiridina koji mogu biti opcijski supstituirani s jednim do dva supstituenta odabrana od R3 i R4.6. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that: HET is a 5-membered heteroaryl ring selected from pyrazolyl and imidazolyl, wherein each heteroaryl ring is substituted with two substituent groups selected from Ra and Rb; whereby Ra and Rb, together with the atoms to which they are attached, form a 5-6 membered heteroaryl ring such that HET is a bicyclic heteroaryl ring selected from imidazopyridine and pyrazolopyridine which may be optionally substituted with one to two substituents selected from R3 and R4. 7. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time, da: X je N; Y je CH; R1 je F; R2 je odabran od metila i Cl; HET je odabran od imidazopiridina i pirazolopiridina koji mogu biti opcijski supstituirani s jednim do dva supstituenta odabrana od R3 i R4; svaki od R3i R4 je neovisno odabran od sljedećih: (a) –H, (b) –O R5, (c) -O-C1-6alkil-O-C1-3 alkil, (d) –O-C3-6 cikloalkil, (e) -C(O)R5, (f) C1-6alkil opcijski supstituiran s jednim do tri –OH, fluorom, heterociklilom opcijski supstituiranim s okso, C3-6 cikloalkilom, –CO2R5, -O-C1-6alkilom, arilom, -N(R5)(R6) ili C(O)N(R5)(R6), (g) C3-6 cikloalkil opcijski supstituiran s jednim do tri –OH, jednim do tri fluora, C1-6alkilom, -OC1-6alkilom, C1-6alkil-OC1-6alkilom, C1-6alkilom-OH, CF3, OC3-6cikloalkilom, -CO2H, -CO2R5, C3-6cikloalkilom, 5-6 članim heteroarilom, C3-6 heterociklilom, N(R5)(R6) ili C(O)N(R5)(R6), (h) –CO2R5, (i) -C(O)N(R5)(R6), (j) –S(O)2N(R5)(R6), (k) –S(O)2-R5, (l) 5-6-člana heteroarilna skupina opcijski supstituirana s jednom do tri skupine odabrane od sljedećih: C1-6alkil, C3-6cikloalkil, halogen, -CF3, -OH, -(CH2)CO2R5, C(O)N(R5)(R6), -N(R5)(R6), -NH-SO2C1-6alkil, C1-6alkoksil, C1-6alkil-O-C1-3 alkil, C1-6alkilhidroksil, C1-3alkil-CN, okso, fenil opcijski supstituiran s halogenom i -S(O)2C1-6alkil, (m) 4-10-člana monociklička, biciklička ili spirociklička heterociklilna skupina koja sadrži N, S ili O, pri čemu je svaki heterocikl opcijski supstituiran s 1-3 supstituenta odabrana od 3-6-članog heterocikličkog prstena, halogena, C1-3alkila ili C1-3alkila-C(O)N(R5)(R6), (n) aril, (o) -N(R5)(R6); svaki od R5 i R6 je neovisno odabran od sljedećih: –H, 4-6-člani heterociklil, -C(O)-C1-3 alkil-C(O)-C1-3 cikloalkil i –(C1-C6)alkil opcijski supstituiran s –OH, C3-6 cikloalkil, -NH-C1-3 alkil ili –N-(C1-3-alkil)2; ili R5 i R6 zajedno s dušikovim atomom na kojega su priključeni, tvore 6-člani heterociklički prsten opcijski supstituiran s metilom.7. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that: X is N; Y is CH; R 1 is F; R 2 is selected from methyl and Cl; HET is selected from imidazopyridine and pyrazolopyridine which may be optionally substituted with one to two substituents selected from R3 and R4; each of R3 and R4 is independently selected from the following: (a) –H, (b) –O R5, (c) -O-C1-6alkyl-O-C1-3 alkyl, (d) –O-C3-6 cycloalkyl, (e) -C(O)R5, (f) C1-6alkyl optionally substituted with one to three –OH, fluorine, heterocyclyl optionally substituted with oxo, C3-6cycloalkyl, –CO2R5, -O-C1-6alkyl, aryl, -N(R5)(R6) or C (O)N(R5)(R6), (g) C3-6 cycloalkyl optionally substituted with one to three –OH, one to three fluorines, C1-6alkyl, -OC1-6alkyl, C1-6alkyl-OC1-6alkyl, C1-6alkyl-OH, CF3, OC3-6cycloalkyl, -CO2H, -CO2R5, C3-6cycloalkyl, 5-6 membered heteroaryl, C3-6 heterocyclyl, N(R5)(R6) or C(O)N(R5)(R6), (h) –CO2R5, (i) -C(O)N(R5)(R6), (j) –S(O)2N(R5)(R6), (k) –S(O)2-R5, (l) 5-6 membered heteroaryl group optionally substituted with one to three groups selected from the following: C1-6alkyl, C3-6cycloalkyl, halogen, -CF3, -OH, -(CH2)CO2R5, C(O)N(R5 )(R6), -N(R5)(R6), -NH-SO2C1-6alkyl, C1-6alkyl, C1-6alkyl-O-C1-3 alkyl, C1-6alkylhydroxyl, C1-3alkyl-CN, oxo, phenyl optional substituted with halogen and -S(O)2C1-6alkyl, (m) a 4-10 membered monocyclic, bicyclic or spirocyclic heterocyclic group containing N, S or O, each heterocycle being optionally substituted with 1-3 substituents selected from a 3-6 membered heterocyclic ring, halogen, C1-3alkyl or C1-3alkyl-C(O)N(R5)(R6), (n) aryl, (o) -N(R 5 )(R 6 ); each of R5 and R6 is independently selected from the following: -H, 4-6 membered heterocyclyl, -C(O)-C1-3 alkyl-C(O)-C1-3 cycloalkyl and -(C1-C6)alkyl optionally substituted with –OH, C3-6 cycloalkyl, -NH-C1-3 alkyl or –N-(C1-3-alkyl)2; or R5 and R6, together with the nitrogen atom to which they are attached, form a 6-membered heterocyclic ring optionally substituted with methyl. 8. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time, da: X je N; Y je CH; R1 je F; R2 je odabran od metila i Cl; HET je imidazopiridin koji može biti supstituiran s jednim do dva supstituenta odabrana od R3 i R4; svaki od R3i R4 je neovisno odabran od sljedećih: (a) –H, (b) –O R5, (c) -O-C1-6alkil-O-C1-3 alkil, (d) –O-C3-6 cikloalkil, (e) -C(O)R5, (f) C1-6alkil opcijski supstituiran s jednim do tri –OH, fluorom, heterociklilom opcijski supstituiranim s okso, C3-6 cikloalkilom, –CO2R5, -O-C1-6alkilom, arilom, -N(R5)(R6) ili C(O)N(R5)(R6), (g) C3-6 cikloalkil opcijski supstituiran s jednim do tri –OH, jednim do tri fluora, C1-6alkilom, -OC1-6alkilom, C1-6alkil-OC1-6alkilom, C1-6alkil-OH, CF3, OC3-6cikloalkilom, -CO2H, -CO2R5, C3-6cikloalkilom, 5-6-članim heteroarilom, C3-6 heterociklilom, N(R5)(R6) ili C(O)N(R5)(R6), (h) –CO2R5, (i) -C(O)N(R5)(R6), (j) –S(O)2N(R5)(R6), (k) –S(O)2-R5, (l) 5-6-člana heteroarilna skupina opcijski supstituirana s jednom do tri skupine odabrane od sljedećih: C1-6alkil, C3-6cikloalkil, halogen, -CF3, -OH, -(CH2)CO2R5, C(O)N(R5)(R6), -N(R5)(R6), -NH-SO2C1-6alkil, C1-6alkoksil, C1-6alkil-O-C1-3 alkil, C1-6alkilhidroksil, C1-3alkil-CN, okso, fenil opcijski supstituiran s halogenom i -S(O)2C1-6alkil, (m) 6-člana monociklička heterociklilna skupina koja sadrži N gdje je heterocikl opcijski supstituiran s 1-3 supstituenta odabrana od 3-6-članog heterocikličkog prstena, halogena, C1-3alkila i C1-3alkila-C(O)N(R5)(R6), (n) aril, (o) -N(R5)(R6); svaki od R5 i R6 je neovisno odabran od sljedećih: –H, 4-6-člani heterociklil, -C(O)-C1-3 alkil-C(O)-C1-3 cikloalkil i –(C1-C6)alkil opcijski supstituiran s –OH, C3-6 cikloalkil, -NH-C1-3 alkil ili –N-(C1-3-alkil)2; ili R5 i R6 zajedno s dušikovim atomom na kojega su priključeni, tvore 6-člani heterociklički prsten opcijski supstituiran s metilom.8. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that: X is N; Y is CH; R 1 is F; R 2 is selected from methyl and Cl; HET is imidazopyridine which may be substituted with one to two substituents selected from R3 and R4; each of R3 and R4 is independently selected from the following: (a) –H, (b) –O R5, (c) -O-C1-6alkyl-O-C1-3 alkyl, (d) –O-C3-6 cycloalkyl, (e) -C(O)R5, (f) C1-6alkyl optionally substituted with one to three –OH, fluorine, heterocyclyl optionally substituted with oxo, C3-6cycloalkyl, –CO2R5, -O-C1-6alkyl, aryl, -N(R5)(R6) or C (O)N(R5)(R6), (g) C3-6 cycloalkyl optionally substituted with one to three –OH, one to three fluorines, C1-6alkyl, -OC1-6alkyl, C1-6alkyl-OC1-6alkyl, C1-6alkyl-OH, CF3, OC3-6cycloalkyl, -CO2H, -CO2R5, C3-6cycloalkyl, 5-6-membered heteroaryl, C3-6 heterocyclyl, N(R5)(R6) or C(O)N(R5)(R6), (h) –CO2R5, (i) -C(O)N(R5)(R6), (j) –S(O)2N(R5)(R6), (k) –S(O)2-R5, (l) 5-6 membered heteroaryl group optionally substituted with one to three groups selected from the following: C1-6alkyl, C3-6cycloalkyl, halogen, -CF3, -OH, -(CH2)CO2R5, C(O)N(R5 )(R6), -N(R5)(R6), -NH-SO2C1-6alkyl, C1-6alkyl, C1-6alkyl-O-C1-3 alkyl, C1-6alkylhydroxyl, C1-3alkyl-CN, oxo, phenyl optional substituted with halogen and -S(O)2C1-6alkyl, (m) a 6-membered monocyclic heterocyclyl group containing N wherein the heterocycle is optionally substituted with 1-3 substituents selected from a 3-6 membered heterocyclic ring, halogen, C1-3alkyl and C1-3alkyl-C(O)N(R5) (R6), (n) aryl, (o) -N(R 5 )(R 6 ); each of R5 and R6 is independently selected from the following: -H, 4-6 membered heterocyclyl, -C(O)-C1-3 alkyl-C(O)-C1-3 cycloalkyl and -(C1-C6)alkyl optionally substituted with –OH, C3-6 cycloalkyl, -NH-C1-3 alkyl or –N-(C1-3-alkyl)2; or R5 and R6, together with the nitrogen atom to which they are attached, form a 6-membered heterocyclic ring optionally substituted with methyl. 9. Spoj prema patentnom zahtjevu 7 ili njegova farmaceutski prihvatljiva sol, naznačen time, da: HET je: [image] opcijski supstituiran s jednim do dva supstituenta odabrana od R3 i R4; svaki od R3i R4 je neovisno odabran od sljedećih: (a) –H, (b) –O R5, (c) -O-C1-6alkil-O-C1-3 alkil, (d) –O-C3-6 cikloalkil, (e) -C(O)R5, (f) C1-6alkil opcijski supstituiran s jednim do tri –OH, fluorom, heterociklilom opcijski supstituiranim s okso, C3-6 cikloalkilom, –CO2R5 , -O-C1-6alkilom, arilom, -N(R5)(R6) ili C(O)N(R5)(R6), (g) C3-6 cikloalkil opcijski supstituiran s jednim do tri –OH, jednim do tri fluora, C1-6alkilom, -OC1-6alkilom, C1-6alkil-OC1-6alkilom, C1-6alkil-OH, CF3, OC3-6cikloalkilom, -CO2H, -CO2R5, C3-6cikloalkilom, 5-6-članim heteroarilom, C3-6 heterociklilom, N(R5)(R6) ili C(O)N(R5)(R6), (h) –CO2R5, (i) -C(O)N(R5)(R6), (j) –S(O)2N(R5)(R6), (k) –S(O)2-R5, (l) 5-6-člana heteroarilna skupina opcijski supstituirana s jednom do tri skupine odabrane od sljedećih: C1-6alkil, C3-6cikloalkil, halogen, -CF3, -OH, -(CH2)CO2R5, C(O)N(R5)(R6), -N(R5)(R6), -NH-SO2C1-6alkil, C1-6alkoksil, C1-6alkil-O-C1-3 alkil, C1-6alkilhidroksil, C1-3alkil-CN, okso, fenil opcijski supstituiran s halogenom i -S(O)2C1-6alkil, (m) 4-10-člana monociklička, biciklička ili spirociklička heterociklilna skupina koja sadrži N, S ili O, pri čemu je svaki heterocikl opcijski supstituiran s 1-3 supstituenta odabrana od 3-6-članog heterocikličkog prstena, halogena, C1-3alkila, i C1-3alkila-C(O)N(R5)(R6), (n) aril, (o) -N(R5)(R6); svaki od R5 i R6 je neovisno odabran od sljedećih: –H, 4-6-člani heterociklil, -C(O)-C1-3 alkil-C(O)-C1-3 cikloalkil i –(C1-C6)alkil opcijski supstituiran s –OH, C3-6 cikloalkil, -NH-C1-3 alkil ili –N-(C1-3-alkil)2; ili R5 i R6 zajedno s dušikovim atomom na kojega su priključeni, tvore 6-člani heterociklički prsten opcijski supstituiran s metilom.9. The compound according to patent claim 7 or its pharmaceutically acceptable salt, characterized in that: HET is: [image] optionally substituted with one to two substituents selected from R3 and R4; each of R3 and R4 is independently selected from the following: (a) –H, (b) –O R5, (c) -O-C1-6alkyl-O-C1-3 alkyl, (d) –O-C3-6 cycloalkyl, (e) -C(O)R5, (f) C1-6alkyl optionally substituted with one to three –OH, fluorine, heterocyclyl optionally substituted with oxo, C3-6 cycloalkyl, –CO2R5 , -O-C1-6alkyl, aryl, -N(R5)(R6) or C (O)N(R5)(R6), (g) C3-6 cycloalkyl optionally substituted with one to three –OH, one to three fluorines, C1-6alkyl, -OC1-6alkyl, C1-6alkyl-OC1-6alkyl, C1-6alkyl-OH, CF3, OC3-6cycloalkyl, -CO2H, -CO2R5, C3-6cycloalkyl, 5-6-membered heteroaryl, C3-6 heterocyclyl, N(R5)(R6) or C(O)N(R5)(R6), (h) –CO2R5, (i) -C(O)N(R5)(R6), (j) –S(O)2N(R5)(R6), (k) –S(O)2-R5, (l) 5-6 membered heteroaryl group optionally substituted with one to three groups selected from the following: C1-6alkyl, C3-6cycloalkyl, halogen, -CF3, -OH, -(CH2)CO2R5, C(O)N(R5 )(R6), -N(R5)(R6), -NH-SO2C1-6alkyl, C1-6alkyl, C1-6alkyl-O-C1-3 alkyl, C1-6alkylhydroxyl, C1-3alkyl-CN, oxo, phenyl optional substituted with halogen and -S(O)2C1-6alkyl, (m) a 4-10 membered monocyclic, bicyclic or spirocyclic heterocyclic group containing N, S or O, each heterocycle being optionally substituted with 1-3 substituents selected from a 3-6 membered heterocyclic ring, halogen, C1-3alkyl , and C1-3alkyl-C(O)N(R5)(R6), (n) aryl, (o) -N(R 5 )(R 6 ); each of R5 and R6 is independently selected from the following: -H, 4-6 membered heterocyclyl, -C(O)-C1-3 alkyl-C(O)-C1-3 cycloalkyl and -(C1-C6)alkyl optionally substituted with –OH, C3-6 cycloalkyl, -NH-C1-3 alkyl or –N-(C1-3-alkyl)2; or R5 and R6, together with the nitrogen atom to which they are attached, form a 6-membered heterocyclic ring optionally substituted with methyl. 10. Spoj prema patentnom zahtjevu 7 ili njegova farmaceutski prihvatljiva sol, naznačen time, da: HET je: [image] opcijski supstituiran s jednim do dva supstituenta odabrana od R3 i R4.10. The compound according to patent claim 7 or its pharmaceutically acceptable salt, characterized in that: HET is: [image] optionally substituted with one to two substituents selected from R3 and R4. 11. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time, da: HET je: [image] opcijski supstituiran s R3, ili HET je: [image] , ili HET je odabran od sljedećih: [image] .11. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that: HET is: [image] optionally substituted with R3, or HET is: [image] , or The HET is selected from the following: [image] . 12. Spoj prema patentnom zahtjevu 1 ili njegova farmaceutski prihvatljiva sol, naznačen time, da: X je N; Y je CH; R1 je F; R2 je metil; HET je: [image] , [image] i [image] R3je metoksi; i R4je [image] .12. The compound according to claim 1 or its pharmaceutically acceptable salt, characterized in that: X is N; Y is CH; R 1 is F; R 2 is methyl; HET is: [image] , [image] and [image] R 3 is methoxy; and R4 is [image] . 13. Spoj prema patentnom zahtjevu 1, naznačen time, da je spoj odabran iz skupine koja se sastoji od sljedećih: [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] 13. Compound according to claim 1, characterized in that the compound is selected from the group consisting of the following: [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] [image] 14. Spoj prema bilo kojem od patentnih zahtjeva 1 i 13, naznačen time, da ima sljedeću strukturu: [image] .14. A compound according to any of claims 1 and 13, characterized in that it has the following structure: [image] . 15. Spoj prema bilo kojem od patentnih zahtjeva 1 i 13, naznačen time, da ima sljedeću strukturu: [image] .15. A compound according to any of claims 1 and 13, characterized in that it has the following structure: [image] . 16. Spoj prema bilo kojem od patentnih zahtjeva 1 i 13, naznačen time, da ima sljedeću strukturu: [image] .16. A compound according to any of claims 1 and 13, characterized in that it has the following structure: [image] . 17. Spoj prema bilo kojem od patentnih zahtjeva 1 i 13, naznačen time, da ima sljedeću strukturu: [image] .17. A compound according to any of claims 1 and 13, characterized in that it has the following structure: [image] . 18. Spoj prema bilo kojem od patentnih zahtjeva 1 i 13, naznačen time, da ima sljedeću strukturu: [image] .18. A compound according to any of claims 1 and 13, characterized in that it has the following structure: [image] . 19. Spoj prema bilo kojem od patentnih zahtjeva 1 i 13, naznačen time, da ima sljedeću strukturu: [image] .19. A compound according to any of claims 1 and 13, characterized in that it has the following structure: [image] . 20. Spoj prema bilo kojem od patentnih zahtjeva 1 i 13, naznačen time, da ima sljedeću strukturu: [image] .20. A compound according to any of claims 1 and 13, characterized in that it has the following structure: [image] . 21. Spoj prema bilo kojem od patentnih zahtjeva 1 i 13, naznačen time, da ima sljedeću strukturu: [image] .21. A compound according to any of claims 1 and 13, characterized in that it has the following structure: [image] . 22. Spoj prema bilo kojem od patentnih zahtjeva 1 i 13, naznačen time, da ima sljedeću strukturu: [image] .22. A compound according to any of claims 1 and 13, characterized in that it has the following structure: [image] . 23. Spoj prema bilo kojem od patentnih zahtjeva 1 i 13, naznačen time, da ima sljedeću strukturu: [image] .23. A compound according to any of claims 1 and 13, characterized in that it has the following structure: [image] . 24. Farmaceutski prihvatljiva sol, naznačena time, da je od spoja prema bilo kojem od patentnih zahtjeva 13 do 23.24. Pharmaceutically acceptable salt, characterized in that it is of the compound according to any one of patent claims 13 to 23. 25. Farmaceutski pripravak, naznačen time, da obuhvaća spoj prema patentnom zahtjevu 1, ili njegovu farmaceutski prihvatljivu sol, i najmanje jedan farmaceutski prihvatljiv nosač.25. Pharmaceutical preparation, characterized in that it comprises the compound according to patent claim 1, or its pharmaceutically acceptable salt, and at least one pharmaceutically acceptable carrier. 26. Spoj prema bilo kojem od patentnih zahtjeva 1 do 24, naznačen time, da se upotrebljava u liječenju autoimune bolesti ili alergijskog poremećaja.26. The compound according to any one of claims 1 to 24, characterized in that it is used in the treatment of an autoimmune disease or an allergic disorder. 27. Spoj za uporabu prema patentnom zahtjevu 26, naznačen time, da je autoimuna bolesti ili alergijski poremećaj odabrana/odabran od sljedećih: reumatoidni artritis, psorijaza, sustavni eritematozni lupus, lupus nefritis, skleroderma, astma, kronična opstrukcijska plućna bolest (KOPB), alergijski rinitis, alergijski ekcem, multipla skleroza, mladenački reumatoidni artritis, mladenački idiopatski artritis, dijabetes tipa I, upalna bolest crijeva, bolest – usadak protiv domaćina, psorijatički artritis, reaktivni artritis, ankilozni spondilitis, Crohnova bolest, ulcerativni kolitis, uveitis i ne-radiografička spondiloartropatija.27. Compound for use according to patent claim 26, characterized in that the autoimmune disease or allergic disorder is selected from the following: rheumatoid arthritis, psoriasis, systemic lupus erythematosus, lupus nephritis, scleroderma, asthma, chronic obstructive pulmonary disease (COPD), allergic rhinitis, allergic eczema, multiple sclerosis, juvenile rheumatoid arthritis, juvenile idiopathic arthritis, type I diabetes, inflammatory bowel disease, graft-versus-host disease, psoriatic arthritis, reactive arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, uveitis and non- radiographic spondyloarthropathy.
HRP20201494TT 2016-09-15 2020-09-18 Heteroaryl carboxamide compounds as inhibitors of ripk2 HRP20201494T1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662394779P 2016-09-15 2016-09-15
EP17768914.8A EP3512833B1 (en) 2016-09-15 2017-09-06 Heteroaryl carboxamide compounds as inhibitors of ripk2
PCT/US2017/050197 WO2018052772A1 (en) 2016-09-15 2017-09-06 Heteroaryl carboxamide compounds as inhibitors of ripk2

Publications (1)

Publication Number Publication Date
HRP20201494T1 true HRP20201494T1 (en) 2020-12-11

Family

ID=59901598

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201494TT HRP20201494T1 (en) 2016-09-15 2020-09-18 Heteroaryl carboxamide compounds as inhibitors of ripk2

Country Status (32)

Country Link
US (2) US10138241B2 (en)
EP (1) EP3512833B1 (en)
JP (1) JP6733050B2 (en)
KR (1) KR102472736B1 (en)
CN (1) CN110023290B (en)
AR (1) AR109650A1 (en)
AU (1) AU2017327539B2 (en)
BR (1) BR112019003320B1 (en)
CA (1) CA3037141A1 (en)
CL (1) CL2019000476A1 (en)
CO (1) CO2019001181A2 (en)
CY (1) CY1123494T1 (en)
DK (1) DK3512833T3 (en)
EA (1) EA038128B1 (en)
ES (1) ES2816003T3 (en)
HR (1) HRP20201494T1 (en)
HU (1) HUE051551T2 (en)
IL (1) IL265062B (en)
LT (1) LT3512833T (en)
MA (1) MA46229B1 (en)
MX (1) MX2019003026A (en)
NZ (1) NZ750416A (en)
PE (1) PE20190979A1 (en)
PH (1) PH12019500497A1 (en)
PL (1) PL3512833T3 (en)
PT (1) PT3512833T (en)
RS (1) RS60729B1 (en)
SA (1) SA519401322B1 (en)
SI (1) SI3512833T1 (en)
TW (1) TWI749062B (en)
UA (1) UA123287C2 (en)
WO (1) WO2018052772A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4067368A1 (en) 2016-06-01 2022-10-05 Athira Pharma, Inc. Compounds
JP6932771B2 (en) * 2016-09-15 2021-09-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pyridine and pyrazine compounds as inhibitors of RIPK2
MA46229B1 (en) 2016-09-15 2020-10-28 Boehringer Ingelheim Int Heteroaryl carboxamide compounds as inhibitors of ripk2
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2020132384A1 (en) * 2018-12-21 2020-06-25 Celgene Corporation Thienopyridine inhibitors of ripk2
AR118471A1 (en) * 2019-03-22 2021-10-06 Takeda Pharmaceuticals Co DERIVATIVES OF PIRROL AND IMIDAZOLE FUSED WITH PYRIDINE AS INHIBITORS OF RIPK2
WO2023239941A1 (en) 2022-06-10 2023-12-14 Interline Therapeutics Inc. Imidazo(1,2-a)pyridine derivatives as ripk2 inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060022649A (en) 2003-05-01 2006-03-10 브리스톨-마이어스 스큅 컴퍼니 Aryl-substituted pyrazole-amide compounds useful as kinase inhibitors
AR060635A1 (en) 2006-04-27 2008-07-02 Banyu Pharma Co Ltd DERIVATIVES OF 1,2-DIHIDRO-3H-PIRAZOLO [3,4-D] PIRIMIDIN-3-ONA, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THEIR USE IN THE TREATMENT OF CANCER
AU2007271089A1 (en) 2006-07-07 2008-01-10 Boehringer Ingelheim International Gmbh Phenyl substituted heteroaryl-derivatives and use thereof as anti-tumor agents
CN101528717B (en) 2006-11-09 2013-04-24 弗·哈夫曼-拉罗切有限公司 Thiazole and oxazole-substituted arylamides
CA2716385A1 (en) 2008-02-27 2009-09-03 Lars Thore Burgdorf Carboxamide-heteroaryl derivatives for the treatment of diabetes
CN101671336B (en) 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 Aromatic heterocyclic pyridine derivatives and analogs and preparation method and application thereof
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US20130023532A1 (en) 2010-03-26 2013-01-24 Casillas Linda N Indazolyl-pyrimidines as kinase inhibitors
US20130018039A1 (en) * 2010-03-31 2013-01-17 Bodmer Vera Q Imidazolyl-imidazoles as kinase inhibitors
AR091490A1 (en) 2012-06-19 2015-02-11 Bristol Myers Squibb Co IAP ANTAGONISTS
TWI592417B (en) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 Prodrugs of amino quinazoline kinase inhibitor
US20140142129A1 (en) 2012-11-20 2014-05-22 Celgene Avilomics Research, Inc, Methods of treating a disease or disorder associated with bruton's tyrosine kinase
LT2953942T (en) * 2013-02-06 2018-02-12 Bayer Cropscience Aktiengesellschaft Halogen-substituted pyrazole derivatives as pesticides
US9725452B2 (en) 2013-03-15 2017-08-08 Presidents And Fellows Of Harvard College Substituted indoles and pyrroles as RIP kinase inhibitors
EP3057956B1 (en) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
CA2935646A1 (en) 2014-01-03 2015-07-09 Bayer Animal Health Gmbh Novel pyrazolyl-heteroarylamides as pesticides
CN107454899B (en) * 2014-10-27 2020-05-29 大学健康网络 RIPK2 inhibitors and methods of treating cancer therewith
EP3504187A4 (en) 2016-08-24 2020-05-06 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
JP6932771B2 (en) 2016-09-15 2021-09-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Pyridine and pyrazine compounds as inhibitors of RIPK2
MA46229B1 (en) 2016-09-15 2020-10-28 Boehringer Ingelheim Int Heteroaryl carboxamide compounds as inhibitors of ripk2

Also Published As

Publication number Publication date
US20190048000A1 (en) 2019-02-14
AU2017327539B2 (en) 2020-12-24
IL265062B (en) 2021-04-29
AU2017327539A1 (en) 2019-02-21
EA038128B1 (en) 2021-07-09
PH12019500497A1 (en) 2019-12-11
SI3512833T1 (en) 2020-11-30
DK3512833T3 (en) 2020-10-12
SA519401322B1 (en) 2022-05-10
KR102472736B1 (en) 2022-12-02
HUE051551T2 (en) 2021-03-01
CO2019001181A2 (en) 2019-02-19
TWI749062B (en) 2021-12-11
PL3512833T3 (en) 2021-01-11
KR20190047046A (en) 2019-05-07
US20220081437A1 (en) 2022-03-17
US20180072717A1 (en) 2018-03-15
CY1123494T1 (en) 2022-03-24
CL2019000476A1 (en) 2019-05-31
ES2816003T3 (en) 2021-03-31
JP2019529407A (en) 2019-10-17
TW201823227A (en) 2018-07-01
CA3037141A1 (en) 2018-03-22
US11130754B2 (en) 2021-09-28
EA201990678A1 (en) 2019-09-30
CN110023290B (en) 2022-08-12
NZ750416A (en) 2022-04-29
CN110023290A (en) 2019-07-16
PT3512833T (en) 2020-09-24
JP6733050B2 (en) 2020-07-29
PE20190979A1 (en) 2019-07-09
MA46229B1 (en) 2020-10-28
BR112019003320A2 (en) 2019-06-04
MA46229A (en) 2019-07-24
US10138241B2 (en) 2018-11-27
BR112019003320B1 (en) 2024-02-20
UA123287C2 (en) 2021-03-10
LT3512833T (en) 2020-10-12
EP3512833B1 (en) 2020-07-29
RS60729B1 (en) 2020-09-30
EP3512833A1 (en) 2019-07-24
AR109650A1 (en) 2019-01-09
WO2018052772A1 (en) 2018-03-22
MX2019003026A (en) 2019-07-01

Similar Documents

Publication Publication Date Title
HRP20201494T1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
HRP20191579T1 (en) Compounds as modulators of ror gamma
HRP20210745T1 (en) Substituted tetrahydroquinolinone compounds as ror gamma modulators
JP2017511357A5 (en)
HRP20191364T1 (en) Heteroaryl sik inhibitors
JP2013525433A5 (en)
HRP20200179T1 (en) Heteroaryl compounds as irak inhibitors and uses thereof
HRP20161127T1 (en) Indazolyl triazole derivatives as irak inhibitors
HRP20211583T1 (en) Thienopyridines and benzothiophenes useful as irak4 inhibitors
ES2733927T3 (en) Condensed imidazole and pyrazole derivatives as modulators of TNF activity
ES2775535T3 (en) Benzotriazole derivatives as modulators of TNF activity
RU2014106020A (en) VTK INHIBITORS
HRP20191799T1 (en) 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
HRP20200016T1 (en) Amide substituted thiazoles as modulators of rorgammat
WO2019193540A1 (en) Heteroaryl derivatives of formula (i) as atf4 inhibitors
HRP20231690T1 (en) Selective inhibitors of nlrp3 inflammasome
HRP20170695T1 (en) Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
ES2730942T3 (en) Triazolopyridine derivatives as modulators of TNF activity
RU2017134551A (en) NEW DIHYDROPYRIDOISOCHINOLINONES AND THEIR PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF INFLAMMATORY DISORDERS
RU2013151803A (en) BICYCLIC HETEROCYCLIC COMPOUNDS AND THEIR APPLICATIONS IN THERAPY
JP2014516074A5 (en)
JP2017501234A5 (en)
CN110896634A (en) 2- (4-chlorophenoxy) -N- ((1- (2- (4-chlorophenoxy) ethynylazetidin-3-yl) methyl) acetamide derivatives and related compounds as ATF4 inhibitors for the treatment of cancer and other diseases
HRP20230595T1 (en) Inhibitors of lysine specific demethylase-1
WO2015101928A1 (en) Fused thiophene and thiazole derivatives as ror gamma modulators